Figure 5.

The inclusion of salicylic acid increases the ability of anti-CDK2 antibody to immunoprecipitate CDK2 from naïve cell lysates and recombinant CDK2 protein. A, anti-cyclin A2 antibody (cat. Number ab32386; Abcam) immunoblots of anti-CDK2 immunoprecipitates (cat. Number-05-596, EMD Millipore), showing the presence of increased levels of cyclin A2 with increased concentration of salicylic acid. In this blot, the area that has cyclin A2 bands are only shown. B, anti-CDK2 antibody immunoblots of the anti-CDK2 immunoprecipitates, shows the presence of increased levels of CDK2 with increased concentrations of salicylic acid. C, shows the results of the in-vitro kinase assay performed on anti-CDK2 immunoprecipitates in an experiment similar to figure 5A. For the experiment in 5C, salicylic acid was pre-incubated with lysate before immunoprecipitation, but not included in the kinase assay. D, shows the results of in-vitro kinase assay performed on anti-CDK2 immunoprecipitates. For the experiments in Fig. 5D, lysates were not pre-incubated with salicylic acid before immunoprecipitation, but was included during the kinase assay. E, anti-CDK2 immunoblot of anti-CDK2 immunoprecipitate of recombinant CDK2, immunoprecipitation was carried out in the presence of increasing concentration of salicylic acid. Ig-H, immunoglobulin heavy chain, Ig-L immunoglobulin light chain.